Notably, the incidence of grade 3-4 hypertension (6.5%) and thyroid dysfunction (4.3%) exceeded rates observed in advanced non-small cell lung cancer (NSCLC) cohorts treated with PD-1 inhibitors plus Anlotinib (grade 3-4 TRAEs: ~40%) (24). Here, PDCD1 is linked to non-small cell lung carcinoma.